We kicked 2023 off strong with our first webinar led by Dr. Chris Corton, Molecular Toxicologist in the Center for Computational Toxicology and Exposure at the U.S Environmental Protection Agency (EPA). Gene expression biomarkers are becoming increasingly important tools to assess mode of action (MOA), determine benchmark dose, and define point of departure for risk assessment. We welcomed Chris to …
The second November installment of our webinar series is with Carole Yauk, PhD, University of Ottawa took place on November 29th at 11 ET. Dr. Yauk will explored the utility of error-corrected next-generation sequencing to quantify and characterize mutations. What you’ll learn: Introduction to error-corrected next-generation sequencing (ecNGS) and its advantages over conventional approaches in chemical mutagenicity assessment; Proof of …
The next installment of our webinar series is with Alexandra Long, PhD, from Health Canada. Alexandra will discuss NAMs as they relate to genetic toxicity. Dr. Long will provide an overview of an integrated, multi-endpoint, higher throughput, in vitro NAM platform, termed GeneTox21, led by Health Canada scientists, for the assessment of chemically induced genetic toxicity. What you’ll learn: The value …
Please join us for our next webinar installment with Dr. Holger Behrsing who will provide an overview of respiratory toxicology and discuss the different types of test systems that provide more relevant data and benefits. What you’ll learn: Exposure to in vitro/ex vivo pulmonary models used to evaluation complex human pulmonary adverse events How 3D test systems differ and …
Please join Dr. Amy Clippinger and Dr. Andreas Stucki as they share their experience with New Approach Methods and regulatory testing; walking us through their case study on Respiratory Toxicity. What you’ll learn: To gain confidence in new approach methodologies (NAMs) for predicting human health effects, it is essential to focus on the relevance of the test system to human …
In this webinar, Pamela Bachour El Azzi, PhD discussed the different applications of HepaRG cells: induction studies, DILI (cholestasis, steatosis) and the 3D systems.What you’ll learn: Coverage of key information about HepaRG cell model and its benefits The use of HepaRG cells for CYP induction and hepatotoxicity studies HepaRG cell engineering and modes of culture All registered participants will receive …
We just showcased our new Chief Scientific Officer, Leslie Recio, PhD, DABTin our May 10th webinar. Les discussed integrating traditional genetic toxicology endpoints with genomic profiling to assess genotoxicity in the HepaRG™ cell platform. He furthere explained how high throughput comet assay using CometChip® technology, a single cell array platform developed at MIT, flow cytometry-based micronucleus (MN) assay, and toxicogenomics …